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Abstract 
Background: Protein aggregation is a biological event observed in expression systems in which the recombinant 
protein is produced under stressful conditions surpassing the homeostasis of the protein quality control system. In 
addition, protein aggregation is also related to conformational diseases in animals as transmissible prion diseases or 
non‑transmissible neurodegenerative diseases including Alzheimer, Parkinson’s disease, amyloidosis and multiple sys‑
tem atrophy among others. At the molecular level, the presence of aggregation‑prone domains in protein molecules 
act as seeding igniters to induce the accumulation of protein molecules in protease‑resistant clusters by intermolecu‑
lar interactions.
Results:   In this work we have studied the aggregating‑prone performance of a small peptide (L6K2) with additional 
antimicrobial activity and we have elucidated the relevance of the accompanying scaffold protein to enhance the 
aggregating profile of the fusion protein. Furthermore, we demonstrated that the fusion of L6K2 to highly soluble 
recombinant proteins directs the protein to inclusion bodies (IBs) in E. coli through stereospecific interactions in the 
presence of an insoluble protein displaying the same aggregating‑prone peptide (APP).
Conclusions: These data suggest that the molecular bases of protein aggregation are related to the net balance 
of protein aggregation potential and not only to the presence of APPs. This is then presented as a generic plat‑
form to generate hybrid protein aggregates in microbial cell factories for biopharmaceutical and biotechnological 
applications.
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Background
Protein aggregation is an event widespread distributed 
from bacteria to animals. In bacteria, it has been related 
to stress states with the deployment of a complex protein 
network to compensate for the reduction of the ability 
of the cells to cope with the conformational stress [1]. 
In contrast, in yeast, protein aggregation is an inher-
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aggregation is also observed in pathological states related 
to conformational diseases [3], but is also associated to 
the formation of hormone aggregates in secretory gran-
ules [4].
During recombinant protein production, the detec-
tion of protein aggregates is a common outcome and is 
observed in both eukaryotic and prokaryotic expression 
systems [5, 6]. Bioinformatic tools are available for pre-
diction of protein and peptide solubility and to identify 
aggregation-prone hot spots in the amino acid sequence, 
which can be modified during the design of recombinant 
genes [7–9]. However, changes in the primary structure 
of the natural proteins may lead to secondary effects as 
the appearance of immunogenic epitopes [10]. Therefore, 
the aggregation propensity of the produced protein may 
be reduced by lowering the transcription and transla-
tion rates of the gene, keeping intact the original amino 
acid sequence [11]. The main variables include the media 
composition, incubation temperature, promoter strength 
and inductor concentration among others [12].
In prokaryotes, the solubility of proteins is controlled 
by the protein quality control system, a complex network 
of protein factors involved in protein folding, unfolding 
and degradation [13]. In bacteria, aggregates, known as 
inclusion bodies (IBs), are dynamic protein clusters from 
which solubilized active protein conformers are released 
under physiological conditions [14–16]. In fact, recent 
experimental approaches have revealed the ability of 
active IBs to rescue enzymatic activities in cell cultures 
and to target cancer stem cells in cancer animal mod-
els [17–21]. Therefore, IBs are envisioned as depots of 
recombinant protein with the capacity to release the pro-
tein of interest from a complex and stable scaffold that 
protects the biological activity of the embed protein over 
time. Therefore, the enhancement of protein aggregation 
in this type of nanostructures is gaining interest. In fact, 
bioprocess design during recombinant protein produc-
tion has been shown to impact the size of the IBs and 
the physicochemical quality of the recombinant protein 
achieving constant production of IBs [22–24]. In addi-
tion, aggregation propensity of recombinant proteins in 
expression systems may be enhanced by the addition of 
aggregation-prone peptides (APPs) in the design of the 
coding DNA sequence of the gene [25]. APP promote 
the establishment of intermolecular interactions between 
protein species enhancing the tendency of the resulting 
complexes to accumulate in the insoluble cell fraction 
[26]. Aggregation domains can be found in nature, in par-
ticular, several protein domains have been shown to pos-
sess such aggregation capacity, including a variant of the 
human β-amyloid peptide (Aβ42 (F19D)) [27], a mutant 
of the maltose binding protein (MalE31) [28], and the 
cellulose-binding domain of Clostridium cellulovorans 
(CBDclos) [29], among others. Another peptide with 
high capacity to enhance protein aggregation is VP1, a 
peptide sequence present in the VP1 structural protein of 
the Foot-and-mouth disease virus [26]. Due to safety and 
regulatory purposes, the use of viral protein domains, as 
VP1, is not suitable for some applications. For that rea-
son, the development of novel APPs is of great interest.
In this study, we have selected a small APP of 8 amino 
acids in length (L6K2) to study the potential of this type 
of peptides to enhance the aggregation propensity of 
soluble proteins [30]. In addition, we have amplified its 
aggregating potential by protein engineering and demon-
strated the antimicrobial activity of this type of amphi-
pathic alpha-helices. We have also analyzed the role of 
stereospecific interactions in the aggregation of heterolo-
gous recombinant proteins in the presence of L6K2-con-
taining peptides, providing a platform to obtain hybrid 
IBs inside the cells. These results have relevant implica-
tions in the biopharmaceutical and biotechnological 
applications of IBs.
Results and discussion
Modulation of recombinant protein solubility in ClearColi 
cells
In order to study the performance of APP fused to 
recombinant proteins in the endotoxin free ClearColi™ 
expression system, two model soluble proteins; iRFP 
(near-infrared fluorescent protein) and GFP (green fluo-
rescence protein) were selected as scaffolds and fused to 
the surfactant-like peptide L6K2, previously described as 
APP (Fig. 1a) [14].
In transformed ClearColi cells, recombinant H6iRFP 
protein was equally distributed in both soluble and insol-
uble cell fractions (Fig.  1b, c). As expected, upon L6K2 
fusion, a different distribution pattern was observed, 
where most of the protein was located in the insoluble 
cell fraction, suggesting an increased aggregation ten-
dency for this fusion protein (Fig.  1b, c). The change in 
solubility pattern was achieved within 1 h of induction 
and was maintained for up to 5 h (Fig. 1b). As a model 
APP, with high ability to enhance aggregation tendency of 
recombinant proteins, VP1 from the capsid protein of the 
Foot-and-mouth disease virus [26, 27] was fused to GFP 
(Fig.  1a). As expected, most of the protein signal in the 
sample was detected in the insoluble cell fraction (Fig. 1b, 
c). In contrast, the recombinant H6GFPL6K2 was mostly 
detected in the soluble cell fraction (Fig.  1b, c). These 
results indicated that the aggregation propensity of a 
recombinant protein may be modulated by APP although 
the solubility tendency of the scaffold protein may coun-
teract this effect (compare solubility of iRFP and GFP 
when fused to L6K2 in Fig. 1b, c). In the case of VP1, the 
aggregation tendency overcome the high solubility of the 
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GFP, while GFP solubility was not affected by the L6K2 
addition (compare solubility of GFP when fused to VP1 
or L6K2 in Fig. 1b, c).
Impact of APP length on protein solubility in ClearColi cells
As the ability of L6K2 to reduce solubility of GFP was not 
significant while it was effective in iRFP, we decided to 
evaluate the effect of peptide length in the solubility of 
GFP. For that, we redesigned the H6GFPL6K2 recombi-
nant gene to add at the C-terminus of the GFP sequence, 
different versions of the surfactant-like peptide L6K2 
(Fig. 2a). The aggregating potential of L6K2 peptide was 
amplified by reiteration of leucine and lysine repeats 
in different positions (see Table  1) and analyzed by 
AGGRESCAN software [8]. Selected peptides displayed 
higher hot spot area (HSA) than the original L6K2 pep-
tide. However, only L12K4 and L18K6 showed increased 
normalized hot spot area (NHSA) and increased average 
aggregation-propensity hot spot  (a4vAHS).
  As previously observed, H6GFPL6K2 was detected in 
the soluble cell fraction of transformed ClearColi cells 
(Fig.  2b, c) and consequently, the emitted fluorescence 
was homogenously distributed in the cytosol (Fig.  2d). 
The addition of the L6K2 derived peptides had a positive 
impact in protein aggregation tendency. As expected, the 
distribution of fluorescence in the transformed cells was 
detected in protein clusters (IBs; Fig. 2d and Additional 
file 1: Fig S1a). In fact, we detected two different aggre-
gation patterns in the L6K2 derived constructs. On the 
one hand, the proteins containing serial L6K2 repeats 
((L6K2)x2 and (L6K2)x3) were preferentially detected in 
periplasmic areas around the cells, while the constructs 
containing longer Leucine/Lysine tracks (L12K4 and 
L18K6) were detected as fluorescent cellular pole aggre-
gates. Therefore, the serial L6K2 repeats acted both as 
APP and periplasm localization signals since the fluo-
rescence pattern revealed the clustering of signal in dis-
crete aggregates on the periphery of the cell cytoplasm. 
In addition, the aggregation tendency in L6K2 repeats 
increased with the number of repeats while L12K4 pre-
sented an aggregation pattern like the observed in cells 
expressing the positive control VP1GFP. This aggrega-
tion tendency was not recorded in Western Blot analy-
sis of the soluble and insoluble cell fractions (Fig. 2b, c), 
indicating that the aggregation tendency of the L6K2-
derived peptides may be sensitive to the tested experi-
mental conditions of protein extraction. This was not the 
case of the aggregation pattern of VP1GFP construct that 
was perfectly replicated under confocal laser scanning 
microscopy and SDS-PAGE (Compare VP1GFP data in 
Fig. 2b–d).
Antimicrobial activity of L6K2‑containing recombinant 
proteins
During recombinant gene expression experiments of 
L6K2-containing constructs, the growth of transformed 
E. coli cells was compromised, especially in the case of 
L18K6 (data not shown). At that point, we reasoned 
whether the peptides were toxic to the cell by displaying 
antimicrobial activity. The modeling of the L6K2 derived 
peptides with PEP-FOLD 3 [31–33] displayed amphip-
athic alpha helices in all cases (Additional file  2: Figure 
S2a). The preferred conformation of the L6K2-contain-
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Fig. 1   Effect of the addition of L6K2 in the aggregation propensity of fluorescent proteins. a Schematic representation of the recombinant genes 
is shown displaying protein domains by separate squares. H6 indicates the presence of a Hisx6 tag. PT corresponds to a linker with the indicated 
amino acid sequence. b Comparative aggregation propensity of iRFP and GFP in the presence of L6K2. VP1GFPH6 corresponds to a GFP fused to 
VP1 considered as positive control of the experiment. c Relative solubility (%) of recombinant proteins detailed in panel a analyzed by Western 
Blotting. Equivalent number of transformed ClearColi cells were lysed and soluble and insoluble cells fractions were separated. All proteins were 
detected with anti‑his antibody
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linker, which has been described as a flexible peptide for 
separating protein domains (Additional file  2: Fig. S2b) 
[34]. This configuration has been described in naturally 
produced or synthetic cationic antimicrobial peptides 
(AMP) which have been proposed as a potential new 
class of antimicrobial drugs [35]. The production of small 
peptides is difficult to be reached by recombinant tech-
nologies due to reduced stability, and alternative strate-
gies have been taken to overcome such a main bottleneck 
[36]. One possibility is the fusion of AMP to partner 
proteins for a potential dual effect on the final product. 
First, the reduction of the toxicity of the AMP over the 
expressing host, and the improvement in the stability 
of the peptide in expression systems [37]. However, the 
study of their activity when fused to reporter proteins 
by genetic engineering has not been explored in depth. 
Examples of this strategy include the fusion between 
GWH1 [38] and GFPH6 [14, 39] and the secretory pro-
duction of AMP-containing fusion partners [40]. In those 
studies, the fusion of the AMP to the N-terminus of 
recombinant protein preserved the bactericidal activity 
of the AMP even though with its C-terminus anchored 
by the fusion. Therefore, we analyzed the putative antimi-
crobial activity of the purified soluble versions of H6GF-
PL6K2 and H6GFP(L6K2)X2 proteins and compared 
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Fig. 2   Production of GFP‑containing recombinant proteins fused to aggregation prone peptides in ClearColi. a Schematic representation of 
L6K2‑containing GFP constructs. H6 indicates the presence of a Hisx6 tag. PT corresponds to a linker with the indicated amino acid sequence. VP1 
corresponds to the VP1 structural protein of Foot-and-mouth disease virus with high tendency to aggregate. b Detection of GFP in soluble and 
insoluble cell fractions of ClearColi transformed with expression plasmids containing the corresponding recombinant genes. c Relative solubility 
(%) of recombinant proteins detailed in panel a analized by Western Blotting. d Confocal analysis of ClearColi cultures producing GFP with several 
aggregation‑prone peptides. Arrows indicate the distribution of protein aggregates in the expressing cells
Table 1 Predictions of “hot spots (HS)” of aggregation in aggregating polypeptides by AGGRESCAN [8]
HS hot spot, HSA hot spot area, NHSA normalized HSA, a4vAHS average aggregation-propensity in each HS
Name HS region HS size Sequence HSA NHSA a4vAHS Ref.
L6K2 1–6 6 LLLLLLKK 6.211 1.035 0.949 [22]
(L6K2)x2 1–14 14 LLLLLLKKLLLLLLKK 12.789 0.913 0.865 This study
(L6K2)x3 1–22 22 LLLLLLKKLLLLLLKKLLLLLLKK 19.367 0.880 0.842 This study
L12K4 1–13 13 LLLLLLLLLLLLKKKK 14.625 1.125 1.074 This study
L18K6 1–19 19 LLLLLLLLLLLLLLLLLLKKKKKK 23.025 1.212 1.171 This study
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The results indicated that the antimicrobial activity of 
L6K2-containing recombinant proteins is strain specific 
(Fig. 3), being comparable to the antimicrobial activity of 
GWH1 peptide fused to GFP in E. coli cultures (Fig. 3b). 
In addition, the position of the peptide at each end of the 
scaffold protein did not appear to be relevant to the anti-
microbial activity. On the other hand, the incubation of S. 
aureus with the proteins containing amphipathic alpha-
helices had only a slight effect on cell viability under the 
tested conditions (Fig.  3a). Interestingly, the antimicro-
bial activity of the recombinant proteins was completely 
different when Micrococcus luteus cells were challenged. 
The addition of the purified proteins had a positive effect 
on cell viability at lower concentrations while at the high-
est protein concentration (8 µmol/L) the cell viability 
dropped drastically (Fig. 3c).
As observed in Fig. 3b, the antimicrobial activity of the 
L6K2-containing constructs was detected in E. coli cul-
tures at low protein concentrations. This mechanism may 
explain the cell growth inhibition observed in ClearColi 
cultures transformed with expression vectors with cloned 
L6K2-derived genes. Small cationic or amphipathic mol-
ecules, similar to the ones described in this work, have 
been described as produced by prokaryotes and eukary-
otic organisms as defense against infectious agents. These 
molecules belong to a non-specific ancient system of 
innate immunity and they perform their activity through 
direct interaction with membranes, nucleic acids, protein 
or even activate autolysins [41–44]. In the case of inter-
acting with membranes, they cause the destabilization of 
the cytoplasmic membrane by forming pores or by their 
arrangement parallel to the membrane surface, disrupt-
ing the proton motive force and provoking the leakage of 
vital molecules which lead to cell death. However, even 
though their mechanism of action is nonspecific, it has 
been described a differential efficacy of the same anti-
microbial peptide between Gram-negative and Gram-
positive bacteria [45, 46]. In the case of Gram-positive 
bacteria, apart from membrane disruption, the reaction 
requires further interactions with the cell wall [45].
Pull‑down effect on aggregation tendency of H6GFPL6K2
Aggregation of different proteins may be enhanced by 
the stereospecific interaction of APP in bacteria [26]. In 
that context, we reasoned that the aggregation ability of 
a recombinant protein with the same APP may enhance 
the aggregation tendency of H6GFPL6K2 when produced 
simultaneously in cells. For that purpose, we generated a 
dual expression vector including the gene encoding for 
H6iRFPL6K2, which displayed a high tendency to aggre-
gate beside the gene coding for H6GFPL6K2 to be simul-
taneously expressed. In cells expressing at the same time 
the aggregation prone H6iRFPL6K2 construct and the 
soluble H6GFPL6K2 construct, the fluorescence of the 
GFP shifted from the cytoplasm to polar protein aggre-
gates (IBs) (Fig. 4). The green fluorescence distribution in 
expressing cells was similar to the pattern observed when 
co-expressing VP1GFPH6 and H6iRFPL6K2.
The change in the aggregation propensity of the H6GF-
PL6K2 seemed to be directed by the pull-down ability of 
the L6K2 peptide present in the H6iRFPL6K2 construct. 
The intermolecular interactions between L6K2 present 
in the two proteins enhances the aggregation tendency 
of GFP. In the expressing cells, the newly formed H6GF-
PL6K2, when interacting with H6iRFPL6K2 with a high 
tendency to aggregate was dragged to the insoluble cell 
fraction. Therefore, it may be hypothesized that when two 
























































Fig. 3   Survival curves of microbial cells in the presence of putative antimicrobial peptides fused to GFP protein. a Staphylococcus aureus, b 
Escherichia coli and c. Micrococcus luteus. The results are presented as mean of two replicas for each analyzed point with corresponding standard 
error bar. Similar CFU where seeded on 96‑well plates and the indicated protein concentrations were added to evaluate its effect on cell 
metabolism
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if one of the proteins is still soluble, the protein with the 
highly aggregation propensity may lead the accompany-
ing soluble protein to the insoluble cell fraction through 
coexpression. However, although the secondary structure 
of the iRFP and GFP proteins is not similar (Additional 
file  3: Figure S3), the effect of the iRFP scaffold protein 
in the aggregation enhancement of H6GFPL6K2 may not 
be ruled out. For that reason, a spectral variant of GFP 
(EBFP2; highly similar in amino acid sequence and sec-
ondary structure) was fused to VP1 domain generating 
VP1EBFP2H6 construct (Additional file  4: Figure S4). 
Predictably, when produced recombinantly, this protein 
was mainly accumulated in the insoluble cell fraction 
(Additional file 5: Figure S5).
The distribution of the GFP fluorescence in cells 
simultaneously transformed with plasmids coding 
H6GFPL6K2 and VP1EBFP2H6 was homogeneously dis-
tributed in the cytoplasm of the cells, in agreement with 
the data obtained in the expression experiment of H6GF-
PL6K2 alone (compare the distribution of GFP fluores-
cence in Figs. 2c and 5a, and Additional file 1: Fig. S1b). 
On the other hand, the fluorescence emitted by EBFP2 
fused to VP1 in those cells was mainly detected in polar 
IBs as expected. When VP1GFPH6 was expressed along 
with VP1EBFP2H6, the GFP fluorescence was located 
exclusively at the poles of the cells, as IBs (Fig.  5b and 
Additional file 1: Fig. S1b). The colocalization analysis of 
the fluorescence emission from both proteins indicated 
the preference of H6GFPL6K2 to aggregate in the pres-
ence of the same APP (Fig. 5c) ruling out an aggregating 
role of the scaffold protein in this process. Therefore, 
this result has a direct application for biopharmaceutical 
and biotechnological applications through protein engi-
neering. In fact, these protein nanoclusters have been 
described as a source of soluble active protein obtained 
upon incubation in non-denaturing conditions [14–16] 
and have also been administered as biocompatible depots 
for tumor targeting of therapeutic proteins [17–21]. Fur-
thermore, protein aggregation seems to be a common 
mechanism described in most of the expression systems 
[47–49] that opens up the possibility of expanding this 
type of strategy to proteins that are difficult to produce 
in prokaryotes. Therefore, the fusion of common APP to 
different therapeutic recombinant proteins can induce 
the colocalization of two recombinant proteins in IBs, 
obtaining protein formulations with potential synergic 
activities.
Conclusions
Protein aggregation is a universal event which is associ-
ated to conformational diseases in eukaryotes. In bac-
teria, although it has been described as a symptom of 
metabolic stress resistance, some studies suggest the 
relevance of protein aggregation in physiological adap-
tation to stress [1]. In most of the recombinant protein 
production experiments described so far, a variable por-
tion of the protein accumulated in bacterial IBs. In recent 
years, the use of IBs as active protein deposits has begun 
to be explored for biopharmaceutical and biotechnologi-
cal applications [22, 50]. The current study highlighted 
H6 iRFP PT L6K2
H6 GFP PT L6K2




Fig. 4   Confocal microscopy images of recombinant GFP in co‑expression experiments. a Detection of H6GFPL6K2 in expressing H6iRFPL6K2 
cells. b Detection of VP1GFPH6 in expressing H6iRFPL6K2 cells. A schematic representation of the corresponding constructs is depicted beside the 
confocal Microscopy images
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the ability to enhance protein aggregation by the fusion 
of APPs to recombinant proteins used as baits for the 
capture of soluble proteins. This effect was even observed 
for highly soluble proteins as GFP. In addition, hybrid 
IBs, enriched in two different recombinant proteins, 
were formed through stereospecific interactions between 
common APP. Therefore, the presented data described 
the potential of APP in the control of the aggregation 
propensity of recombinant proteins in biological formu-
lations based on IBs and open up the possible exploration 
of synergic activities of hybrid protein aggregates, pro-




All protein designs were cloned in pETDuet™-1 plasmid 
(Novagen), except for H6iRFP, GFPH6 an GWH1GFPH6, 
which were cloned into NdeI and HindIII sites of plas-
mid pET22b (Novagen). For all pETDuet™-1 derived 
expression vectors, protein-coding DNA fragments 
were inserted in either, MCS1 or MCS2 of pETDuet™-1 
plasmid. In the case of H6GFPL6K2, H6GFP(L6K2)
X2, H6GFP(L6K2)X3, H6GFPL12K4, H6GFPL18K6 
and VP1GFPH6, digestion was performed with NdeI 
and XhoI and insertion into the MCS2. On the other 
hand, H6iRFPL6K2 and VP1EBFP2H6 were digested 
with NcoI and HindIII and inserted into the MCS1. For 
dual expression plasmids, H6iRFPL6K2 + H6GFPL6K2, 
H6iRFPL6K2 + VP1GFPH6, VP1EBFP2H6 + VP1GFPH6 
and VP1EBFP2H6 + H6GFPL6K2 a two-step cloning 
strategy was followed. After the generation of the MCS2 
cloning plasmids (pETDuet-H6GFPL6K2 and pETDuet-
VP1GFPH6), H6iRFPL6K2 and VP1EBFP2H6 frag-
ments were inserted into the MCS1 after digestion with 
NcoI and HindIII. All L6K2-containing protein versions 
included a linker (PT) between GFP and the L6K2 pep-
tide or derivatives as previously described [30].
Expression of recombinant proteins in ClearColi cells
ClearColi BL21 (DE3) was selected as expression host 
for the different versions of the fluorescent proteins. The 
same conditions were applied in all cases. Briefly, after 
transformation with the corresponding expression vector, 
bacterial cells were allowed to growth in lysogenic broth 
(LB) medium supplemented with 100 µg/ml ampicillin in 
a shake flask (250 rpm) at 37 ºC. When cultures reached 
an optical density of approximately 0.5–0.6, protein 
expression was induced by adding 1  mmol/L isopropyl-
β-D-thiogalactopyranoside (IPTG). Protein samples 
were taken at the indicated times (h) postinduction. In 
all cases, bacterial OD was measured and adjusted to 1, 
subsequently cells were collected by centrifugation (5 
minutes, 1,200 g). Resuspended cells were processed for 
VP1 EBFP2 H6 VP1 GFP H6
VP1 EBFP2 H6 H6 GFP PT L6K2a
b
c
Fig. 5   Overlay fluorescence images of H6GFPL6K2 and VP1GFPH6 with VP1EBFP2H6. a Detection of fluorescence emission from H6GFPL6K2 and 
VP1EBFP2H6 coexpressing cell cultures. b Detection of fluorescence emission from VP1GFPL6H6 and VP1EBFP2H6 coexpressing cell cultures. c 
Quantitative colocalization analysis of EBFP2 and GFP fluorescence signals in coexpression experiments. Overlap coefficients between the different 
fluorescences emitted by the fusion proteins VP1EBFP2H6/VP1GFPH6 and VP1EBFP2H6/H6GFPL6K2 expressed in ClearColi cells. Analysis performed 
from images obtained by confocal microscopy. *p < 0.001, one‑way analysis of variance (ANOVA)
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confocal microscopy visualization or to evaluate the rela-
tive protein distribution between the insoluble and solu-
ble cell fractions, in those cases, the expression time was 
set at 3 h.
Evaluation of protein aggregation propensity
Bacterial pellets harboring the expressed proteins were 
resuspended in 1  mL of PBS until a homogeneous sus-
pension was achieved. Bacterial cell disruption was car-
ried out by sonication (1 round of 1 min at 10 % amplitude 
and 1 round of 1 min at 15 % amplitude). Then, the solu-
ble and insoluble cell fractions were separated by cen-
trifugation (15 min, 15,000 g at 4  °C). The insoluble cell 
fraction, containing the cell debris, was resuspended in 
1 mL of PBS, after that, a small aliquot of both fractions, 
soluble and insoluble, was mixed (1:1) with Laemmli 
buffer. Soluble samples were boiled at 90 ºC for 10 min, 
while the insoluble samples were boiled for 40 min. The 
processed samples were charged on SDS-PAGE gels and 
analyzed by Western Blotting with an anti-His mono-
clonal antibody (His Tag Antibody, mAb, Mouse, Gen-
script). Images were acquired with the ChemiDoc™ 
Touch Imaging System (Bio-Rad) and further processing 
was performed with Image Lab Software. Percentage of 
aggregation was calculated based on the numerical band 
intensity value obtained from blotting membrane images. 
For each expression time, the total amount of protein 
(100 %) was considered as the sum of the band intensi-
ties in both, soluble and insoluble cell fractions. There-
fore, percentage of aggregation can be estimated from the 
band intensity value in the insoluble cell fraction.
Visualization of recombinant proteins in ClearColi cells
Bacterial pellets harboring the expressed proteins were 
resuspended in 500 µL of PBS containing 4 % formal-
dehyde. Then, resuspended samples were incubated 10 
minutes at RT and washed twice with PBS. In a glass 
slide, a small drop of ProLong™ Gold Antifade Mountant 
(Thermo) was mixed with 5 µL of the bacterial suspen-
sion. The resultant solution was covered with a cover-
slip and fixed to avoid dehydration. The observation of 
the fluorescent proteins inside bacteria was recorded 
by TCS-SP5 confocal laser scanning microscopy (Leica 
Microsystems). Images were processed using the ImageJ 
software. Colocalization analysis of fluorescent pro-
teins in ClearColi cells were performed by measuring 
the overlap coefficients of 10 regions of interest (ROIs) 
which were compared by one-way analysis of variance 
(ANOVA).
Purification of soluble recombinant proteins fused to APP
For purification of H6GFPL6K2, H6GFP(L6K2)X2 
and GWH1GFPH6, protein expression was induced 
with 0.1  mmol/L isopropyl-β-D-thiogalactopyranoside 
(IPTG) at 20 ºC, overnight. The cell pellet was collected 
(6000  g, 4 ºC, 15 minutes) and resuspended in wash 
buffer (20 mmol/L Tris-HCl, pH 8.0, 500 mmol/L NaCl, 
10  mmol/L imidazole) with ethylenediamine tetra-ace-
tic acid-free protease-inhibitor (complete EDTA-Free, 
Roche). Cells were then disrupted by sonication (1 round 
of 2  min at 10 % amplitude and 10 rounds of 2  min at 
15 % of amplitude) and cell debris was separated from 
soluble fraction by centrifugation (15,000  g at 4 ºC, 45 
minutes). After filtration (0.22 µm), the His-tagged pro-
teins were purified from the soluble fraction by His tag 
affinity chromatography using HiTrap Chelatin HP 1 ml 
column (GE Healthcare) in an ÄKTA purifier FPLC (GE 
Healthcare). The purified fraction was obtained after elu-
tion with a linear gradient of 20 mmol/L Tris-HCl pH 8.0, 
500 mmol/L NaCl, 500 mmol/L imidazole. The purity of 
the different samples was analyzed by TGX gel chemistry 
and Western Blotting. The selected fractions were mixed 
and dialyzed against sodium bicarbonate buffer with salt 
(166 mmol/L NaHCO3, pH 8.0, 333 mmol/L NaCl) and 
protein amounts were quantified by Bradford assay.
Antimicrobial activity of APP‑containing recombinant 
proteins
The antimicrobial activity of H6GFPL6K2, H6GFP(L6K2)
X2 and GWH1GFPH6 was evaluated against three bac-
terial species, E. coli, S. aureus, and M. luteus, using the 
broth micro-dilution method. Different two-fold dilu-
tions of the proteins, ranging from 0.06 to 8 µmol/L, were 
seeded in 96-well plates for each bacterial species. After 
that,  106 CFU/mL of the corresponding bacteria were 
inoculated in each well. Maximal growth was achieved 
in control wells with no protein. Each concentration was 
evaluated in technical duplicates. Wells with 100 µL of 
Mueller Hinton Broth Cation-adjusted medium (MHB-
2, Sigma-Aldrich) were considered as blank solution. 
Growth conditions were stablished in 18 h at 37 ºC. The 
bacterial viability was evaluated using the commercially 
available BacTiter-Glo™ Microbial Cell Viability Assay 
(Promega) following the manufacturer’s instructions. 
Luminescence was measured using the Multilabel Plater 
Reader VICTOR3 (PerkinElmer).
Supplementary Information
The online version contains supplementary material available at https ://doi.
org/10.1186/s1293 4‑021‑01524 ‑3.
Additional file 1: Figure S1. Extended confocal microscopy visualization 
of E. coli ClearColi cells producing the recombinant fluorescent proteins. a 
Visual field of cells producing L6K2‑containing constructs and VP1GFPH6 
(aggregation control) analyzed in Fig. 2. b Visual fields of cells producing 
simultaneously GFP and EBFP2 constructs analyzed in Fig 5. Scale bar 
indicates 4 μm.
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Additional file 2: Figure S2. PEP‑FOLD server‑generated models of 
aggregation prone peptides fused to GFP scaffold protein. a Regular poly‑
peptide helices in a right‑handed alpha‑helical conformation are shown. 
All structures are reproduced at the same scale. b Helical conformation of 
two L6K2‑containing peptides (blue) in the presence of PT linker (grey).
Additional file 3: Figure S3. DNA sequences of recombinant genes 
H6iRFPL6K2 and H6GFPL6K2 used in the study. Translate tool from Expasy 
was used to obtain corresponding amino acid sequences. Clustalw was 
run to align amino acid sequences and Swiss Model to display 3D struc‑
tures of the recombinant proteins.
Additional file 4: Figure S4. DNA sequence of recombinant gene VP1EB‑
FP2H6 used in the study. Translate tool from Expasy was used to obtain 
corresponding amino acid sequence. Clustalw was run to align amino acid 
sequence of GFP and EBFP2. Swiss Model was used to display 3D structure 
of EBFP2 protein.
Additional file 5: Figure S5. Relative solubility (%) of recombinant pro‑
teins. Detection of H6GFPL6K2, VP1GFPH6 and VP1EBFP2H6 in the soluble 
and insoluble cell fractions of ClearColi analyzed by Western Blotting. 
Equivalent number of transformed ClearColi cells were lysed and soluble 
and insoluble cells fractions were separated. All proteins were detected 
with anti‑his antibody. Data are presented as mean ± STD of biological 
triplicate measurements.
Abbreviations
IBs: Inclusion bodies; APP: Aggregation‑prone peptide; iRFP: Near‑infrared 
fluorescent protein; GFP: Green fluorescence protein; HS: Hot spot; HAS: Hot 
spot area; NHSA: Normalized HAS; a4vAHS: Average aggregation‑propensity in 
each HS; AMP: Antimicrobial peptide.
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